| Literature DB >> 32256559 |
Hanna Johansson1,2, Maria Hagströmer1,2,3, Wilhelmus J A Grooten1,2, Erika Franzén1,2,4.
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder for which there is currently only symptomatic treatment. During the last decade, there has been an increased interest in investigating physical exercise as a neuroprotective mechanism in PD. Animal studies have suggested that exercise may in fact induce neuroplastic changes, but evidence in humans is still scarce. A handful of reviews have previously reported on exercise-induced neuroplasticity in humans with PD, but few have been systematic, or have mixed studies on both animals and humans, or focused on one neuroplastic outcome only. Here, we provide a systematic review and metasynthesis of the published studies on humans in this research field where we have also included different methods of evaluating neuroplasticity. Our results indicate that various forms of physical exercise may lead to changes in various markers of neuroplasticity. A narrative synthesis suggests that brain function and structure can be altered in a positive direction after an exercise period, whereas a meta-analysis on neurochemical adaptations after exercise points in disparate directions. Finally, a GRADE analysis showed that the current overall level of evidence for exercise-induced neuroplasticity in people with PD is very low. Our results demonstrate that even though the results in this area point in a positive direction, researchers need to provide studies of higher quality using more rigorous methodology.Entities:
Mesh:
Year: 2020 PMID: 32256559 PMCID: PMC7079218 DOI: 10.1155/2020/8961493
Source DB: PubMed Journal: Neural Plast ISSN: 1687-5443 Impact factor: 3.599
Figure 1PRISMA flow diagram modified from Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6 [7].
Characteristics of included studies, participants, and assessments.
| Study characteristics | Participant characteristics | Assessment details | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
| (1) |
| Age, mean (SD) | Hoehn & Yahr, mean (SD) |
|
| |||
|
|
|
|
|
|
| ||||
| Angelucci et al., [ | (1) Single-arm clinical trial, (2) inpatient, (3) not reported, (4) no/2-3 | 9 | _ | 62.8 (6.7) | _ | 2.1 (0.6) | _ | Blood sampling: levels of | UPDRS II-III, PDQ-39, and 6MWT. |
| Fontanesi et al., [ | (1) Single-arm clinical trial, (2) inpatient, (3) not reported, (4) no/no | 16 | _ | 71.6 (6.8) | _ | 2.7 (0.4) | _ | Blood sampling: evaluation of | UPDRS, 6MWT, BBS, TUG, PDDS, FOG-Q. |
| Frazzitta et al., [ | (1) Randomized controlled trial, (2) inpatient, (3) recruited from patients admitted to a rehabilitation institute, inclusion, (4) no/1–1.5 | 15 | 10 | 67 (5) | 65 (4) | NR | NR | Blood sampling: levels of | UPDRS III (training group was also tested on UPDRS total, BBS, and 6MWT) |
| Zoladz et al., [ | (1) Single-arm clinical trial, (2) outpatient, (3) not reported, (4) no/no | 12 | _ | 70 (10.4)∗ | _ | 2.3(0.7)∗ | _ | Blood sampling: levels of | UPDRS total |
| Batson et al., [ | (1) Case study, (2) outpatient, (3) recruited from previous intervention group, (4) no/no | 1 | _ | 60 | _ | 3 | _ | Imaging: BOLD | None |
| Duchesne et al., [ | (1) Single-arm clinical trial, (2) outpatient (3) not reported, (4) no/1–2 | 19 | _ | 59 (7.11) | _ | 2 (0) | _ | Imaging: BOLD | Cardiovascular fitness evaluated through either a submax- or max-test (bike). Reaction times and accuracy on the serial reaction time task. |
| Maidan et al., [ | (1) Randomized controlled trial, (2) outpatient, (3) convenience sample from another project, (4) 60–90/2–3 | 17 | 17 | 71.2 (1.7) | 71.5 (1.5) | NR | NR | Imaging: BOLD | Gait speed and stride length during usual walking and obstacle negotiation. Global cognitive function, attention and executive function was assessed using a computerized test battery. |
| Shah et al., [ | (1) Randomized controlled trial, (2) outpatient, (3) not reported, (4) 30–65/2–3 | 13 | 14 | 56.5(9.5) | 57.2 (7.1) | NR | NR | Imaging: BOLD | None |
| Carvalho et al., 2016 | (1) Randomized controlled trial, (2) outpatient, (3) recruited from an outpatient rehabilitation department (4) 45–80/1–3 | 5 (AT) and 8 (ST) | 9 | 64.8 (11.9) (AT) | 62.1 (11.7) | 2.6 (0.5) (AT) | 2.3 (0.5) |
| UPDRS I-IV. Chair-stand test, arm curl test, 2-minute step test, chair sit and reach test, back scratch test, 8-foot up and go test, 10 m walk test, and BBS. |
| Fisher et al., [ | (1) Nonrandomized controlled trial, (2) outpatient, (3) recruited from a movement disorder clinic, (4) no/no | 5 | 7 (LI) and 4 (ZI) | NR | NR | NR | NR | Evaluation of corticomotor excitability using single-pulse | UPDRS, 10-meter walk test (both self-selected and as fast as possible) and sit to stand test. |
| Fisher et al., 2013 | (1) Randomized controlled trial, (2) outpatient, (3) subset from ongoing study, (4) no/no | 2 | 2 | 53.5 (2.1) | 56.5 (9.2) | NR | NR | Evaluation of DA-D2R binding potential using | Turning, UPDRS III and total. |
| del Olmo et al., [ | (1) Single-arm clinical trial, (2) outpatient, (3) not reported, (4) no/no | 9 | _ | 61.2(5.2) | _ | 1.9 (0.5) | _ | Evaluation of metabolic brain activity with | Spatiotemporal gait parameters at preferred speed 30 m. Finger tapping for 30 s. |
| Sehm et al., 2013 | (1) Single-arm clinical triala, (2) outpatient, (3) recruited from an outpatient clinic, (4) no/no | 20 | _ | 62.9 (7.1) | _ | 2.1 (0.4) | _ | Evaluation of grey matter volume using structural | BBS; behavioral measure: “Time in target,” i.e, the number of seconds participants were able to keep the platform in a horizontal position. |
∗SD calculated from SEM. Abbreviations: BDNF: brain-derived neutrophic factor; UPDRS: Unified Parkinson's Disease Rating Scale; PDQ-39: Parkinson's Disease Questionnaire-39; 6MWT: 6-minute walk test; BBS: Berg Balance Scale; TUG: Timed Up and Go; NA: not applicable; NR: not reported; EEG: electroencephalogram; CSP: cortical silent period; 8-FT: 8 Foot Up and Go test; BST: Back Scratch Test; CSRT: Chair Sit and Reach Test; ACT: Arm Curl Test; CST: Chair Stand Test; 2-MST: 2-minute step test; 10mWT: 10-meter walk test; TMS: transcranial magnetic stimulation; PET: positron emission tomography.
Description of interventions and results.
| Intervention characteristics | Results | ||||
|---|---|---|---|---|---|
|
|
|
|
|
|
|
| Angelucci et al., [ | Motor rehabilitation consisting of 3 sessions per day: (1) exercises to promote flexibility, relaxation, coordination, posture, and walking, (2) treadmill (aerobic) and Wii fit balance board, (3) motor therapy. | NA | 4 wks | BDNF levels at end comparable to baseline ( | Improvements at end: UPDRS II ( |
|
| |||||
| Fontanesi et al., [ | Multidisciplinary rehab 3 sessions per day: (1) physical therapy including ROM, strength, and balance; (2) aerobic training; and (3) occupational therapy. | NA | 4 wks | Analysis revealed a posttraining upregulation of BDNF-TrkB signaling in the peripheral lymphocytes at the levels of receptors, intracellular mediators, and downstream effectors. | Improvement on all scores: UPDRS total ( |
|
| |||||
| Frazzitta et al., [ | Multidisciplinary rehab 3 sessions per day: (1) cardiovascular warm-up, relaxation, stretching, etc.; (2) balance and gait training on platform and treadmill (aerobic training); and (3) occupational therapy. | Passive | 4 wks | Posttraining analysis revealed increased levels of BDNF in the training group (ES 1.1, | Participants in the training group improved on UPDRS III compared to controls ( |
|
| |||||
| Zoladz et al., [ | Bike (aerobic) at voluntary-rate warm-up and cooldown 10 min each, and 40 min moderate intensity interval exercise in-between. | NA | 8 wks | Posttraining analysis of BDNF levels revealed an increase of 34% ( | Participants decreased their UPDRS-total score significantly after the training period ( |
|
| |||||
| Batson et al., [ | Improvisational dance emphasizing large ROM, changes in base of support and movement speed variability. | NA | 1 wk | Stronger connections between anterior and posterior aspects of Default Mode Network. The basal ganglia became highly interconnected with the premotor cortex. | No other outcomes to report. |
|
| |||||
| Duchesne et al., [ | Bike (aerobic), starting at 20 min and 60% intensity (based on each participant fitness level) and intensified each week until reaching 40 min of training at 80% intensity. | NA | 12 wks | Analysis revealed a posttraining increase in brain responses in the temporal lobes, left ventral striatum, left hippocampus, cerebellar lobules 8 and 9 bilaterally, and right crus. These responses reflected motor sequence learning capacity specifically. | Improvement in aerobic fitness (V02 max) ( |
|
| |||||
| Maidan et al., [ | Treadmill training. Speed and duration of the treadmill was progressed throughout the training period according to each participant's ability. | Treadmill training with added virtual reality component. | 6 wks | Posttraining analysis showed significantly different patterns of brain activation between training arms i Brodmann area 10 ( | Improvements at end: UPDRS II ( |
|
| |||||
| Shah et al., [ | Bike (aerobic) at forced-rate exercise. | Bike (aerobic) at voluntary-rate exercise. | 8 wks | Posttraining analysis revealed that participants exercising at forced-rate showed that the active motor cortex had a stronger connection to the ipsilateral thalamus compared to those participants who pedaled at voluntary-rate. | No other outcomes to report. |
|
| |||||
| Carvalho et al., [ | Treadmill training (aerobic) or strength training. | Calisthenics | 12 wks | EEG analysis showed a higher mean frequency in treadmill and strength training groups compared to calisthenics ( | (Effect size strength training/treadmill/calisthenics) ( |
|
| |||||
| Fisher et al., 2008 | High-intensity body weight-supported treadmill training (aerobic). | Low intensity physical therapy (active and passive ROM training, balance, gait, resistance and functional training) or passive control group. | 8wks | All subjects in the treadmill group showed an increased CSP-duration in both hemispheres after training. No changes were found in the physical therapy group. | Not reported for the TMS subsample. |
|
| |||||
| Fisher et al., 2013 | Treadmill (aerobic), each session aimed at reaching and maintaining a metabolic equivalent of task level greater than 75% of age-adjusted heart rate. | Passive | 8 wks | PET imaging post-training demonstrated a marked increase in Fallypride BP in the dorsal putamen in both individuals. No changes were seen in control subjects. | Exercise subjects demonstrated improved turning performance, while control subjects did not. No participant improved in either UPDRS total or UPDRS III. |
|
| |||||
| del Olmo et al., [ | Gait and fingertapping training with and without rhythmic auditory cues. | NA | 4 wks | PET imaging post-training revealed a metabolic increment in the right cerebellum ( | Coefficient of variation decrement for both fingertapping ( |
|
| |||||
| Sehm et al., 2013 | Balance training using a movable platform. | NA | 6 wks | Imaging analysis revealed a post-training increase in grey matter volume in the right hemisphere of the cerebellum (lobule V–VI) ( | Participants showed a significant increase in DBT (time in target). Results on BBS are not reported. |
Abbreviations: Exp—Experimental group, Con—Control group, BDNF—Brain-derived Neutrophic Factor, UPDRS—Unified Parkinson's Disease Rating Scale, PDQ-39—Parkinson's Disease Questionnaire-39, 6MWT—6-minute walk test, BBS—Berg Balance Scale, TUG—Timed Up and Go, AT—Aerobic training, ST—Strength training, LI—Low intensity, ZI—Zero intensity, NR—Not reported, EEG—Electroencephalogram, CSP—Cortical Silent Period, 8-FT—8 Foot Up and Go test, BST—Back Scratch Test, CSRT—Chair Sit and Reach Test, ACT—Arm Curl Test, CST—Chair Stand Test, 2-MST—2 Minute Step Test, 10mWT—10 meter Walk Test, TMS—Transcranial Magnetic Stimulation, PET—Positron Emission Tomography, BP—Binding Potential.
Narrative synthesis of neuroplastic outcomes from pre- to post-intervention.
| Reference | Quality | Method used to measure neuroplasticity | Specification of signaling type or brain area/s | Direction of change from pre to post-intervention | MA∗ | |
|---|---|---|---|---|---|---|
| Angelucci et al. | 13 | Blood sampling, BDNF serum concentration | 0 | Yes | ||
| Fontanesi et al. | 14 | Blood sampling, TrkB signaling in lymphocytes | pY-TrkB (145 kDa) | + | No | |
| pY-TrkB (95 kDa) | 0 | No | ||||
| NR1 | + | No | ||||
|
| 20 | Blood sampling, BDNF serum concentration | + | Yes | ||
| Zoladz et al. | 15 | Blood sampling, BDNF serum concentration | + | Yes | ||
|
| ||||||
|
| ||||||
| Batson et al. | 6 | fMRI, BOLD signal | Connection between anterior and posterior aspects of Default Mode Network | + | + | No |
| Connection between basal ganglia and premotor cortex | + | + | No | |||
| Duchesne et al. | 14 | fMRI, BOLD signal | Temporal lobes | + | + | No |
| Left ventral striatum | + | + | No | |||
| Left hippocampus | + | + | No | |||
| Cerebellum (lobules 8 and 9 bilaterally and right crus) | + | + | No | |||
|
| 15 | fMRI, BOLD signal | Middle temporal gyrus | − | + | No |
| Shah et al. | 14 | fMRI, BOLD signal | Connection between active motor cortex and ipsilateral thalamus | + | + | No |
|
| 16 | EEG, mean frequency | No significance given to area | + | + | No |
|
| 14 | TMS, CSP duration | CSP-duration in both hemispheres | + | + | No |
|
| 16 | PET, metabolic activity | Dorsal putamen | + | + | No |
| del Olmo et al. | 13 | PET, metabolic activity | Right cerebellum | + | + | No |
| Right parietal lobe | + | + | No | |||
| Right temporal lobe | + | + | No | |||
|
| ||||||
|
| ||||||
| Sehm et al. | 15 | MRI | Right hemisphere of cerebellum∗∗ | + | + | No |
References in bold are of RCT design. Overall quality score assessed with the modified Down and Black checklist, ranging from 0 to 28 with higher scores indicating higher overall quality. Activity and volume indicate whether a change in respective measure increased (+) or decreased (−). Direction indicates change in neuroplastic marker from pre to post-intervention and states whether it was assessed as positive (+), negative (−), or unchanged (0). ∗ indicates whether the study was included in the meta-analysis (MA). ∗∗ as compared to healthy control group. Abbreviations: BDNF—Brain Derived Neurotrophic Factor; TrkB—Tyrosine receptor kinase B; fMRI—Functional Magnetic Resonance Imaging; BOLD—Blood Oxygenated Level Dependent; EEG—Electroencephalogram; TMS—Transcranial Magnetic Stimulation; CSP—Cortical Silent Period; PET—Positron Emission Tomography.
Figure 2Meta-analyses and forest plots of included studies using three different r values, showing effect sizes (Hedges' g) of change in levels of brain-derived neurotrophic factor from pre- to postintervention.
Summary of findings and overall level of evidence as assessed with GRADE.
| All studies | Studies included in the meta-analysis | GRADE domains | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Domain | Method | Total number of participants (no. studies) | Total number of participants (no. studies) | Estimated effect size ( | Phase | Study limitations | Inconsistency | Indirectness | Imprecision | Publication bias | Level of evidence |
| Neurochemical | BDNF level in serum, TrkB signaling in lymphocytes | 61 (4) | 36 (3) | 0.91–1.84 (>0.05) | +++ | − | 0∗ | 0 | − | 0∗∗ | + |
| Brain function | fMRI, EEG, TMS, PET | 132 (8) | NA | NA | |||||||
| Brain structure | MRI | 20 (1) | NA | NA | |||||||
GRADE—Grading of Recommendations Assessment, Development and Evaluation. ∗Heterogenous outcomes. ∗∗None of the included studies were registered in Clinical Trials.